Phase 1 trial of AK101 in patients with moderate to severe psoriasis
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2018
At a glance
- Drugs AK-101 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- 21 Mar 2018 New trial record
- 22 Dec 2017 According to an Akeso Biopharma media release, this trial has been launched at the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, and has begun screening and enrolling patients.
- 11 Oct 2017 According to an Akeso Biopharma media release, China Food and Drug Administration (CFDA) has approved clinical trial application.